Top 10 Global Pharma Seeks Treatment Leaders to Advance Diversity Strategies for a Phase II Cardiology Trial
When it comes to advancing diversity in clinical trials, the challenge is finding healthcare providers (HCPs) with a diverse patient population that are also willing and able to participate. A global top 10 pharma company recently asked H1 to help them identify HCPs for outreach related to their phase II trial on Atherosclerotic Cardiovascular Disease (ASCVD), a type of heart disease caused by consistent high LDL-C levels in the blood that lead to plaque buildup on artery walls.
With an industry leading KOL identification platform, HCP Universe, clinical trial intelligence platform – Trial Landscape and strategic insights team, H1 took on this challenge with a tech-first, data-driven and cross-functional approach to narrow down potential HCPs and curate a list for trial outreach. Now, let’s take a look at how they did it.
Get the case study: Top 10 Global Pharma Seeks Treatment Leaders to Advance Diversity Strategies for a Phase II Cardiology Trial